Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

BACKGROUND Cyclins and cyclin-dependent kinases (CDKs) drive cell division. Of
particular importance to the cancer field are D-cyclins, which activate CDK4 and CDK6. In …

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus
fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ …

Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in
hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole …

Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free
survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy
in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of …